Manufacturers of medicines, Active Pharmaceutical Ingredients (APIs), biologicals (excluding class 1 biologicals), blood and blood components and haematopoietic progenitor cells have responsibilities in relation to:
- during manufacture
- informing the TGA
- licence-specific responsibilities
- GMP inspections
- post-inspection responsibilities.
For Australian manufacturers with licences, many of these responsibilities are legal requirements in the Therapeutic Goods Act 1989- external site and the Therapeutic Goods Regulations 1990- external site. Section 40 of the Therapeutic Goods Act 1989 and Regulations 19 and 20 contain conditions for licence holders.
For overseas manufacturers the same responsibilities and expectations apply, unless otherwise specified.
Key information for industry
-
PageInformation on complying with good manufacturing practice (GMP).
-
-
-
PageUnderstand your record keeping responsibilities.
-
-
PageComply with state, territory and other requirements for manufacturing medicines.
More information
- Good manufacturing practice application decision tree
-
Australian manufacturing licences and overseas GMP certification
- Update to Manufacturing Principles for medicines, APIs & sunscreens
- Release for supply of medicines
- Guidance for TGO 101
- Guidelines for sterility testing of therapeutic goods
- Clearance Application Assistance Tool
TGA Industry Working Group on GMP meetings
Publications
- Code tables
- Process validation for listed and complementary medicines
- Releasing medicines manufactured at multiple sites
Presentations
- Webinar presentation: Remote Inspections from TGA Manufacturing Quality Perspective
- Webinar presentation: Management of GMP compliance signals
- Webinar presentation: GMP inspection trends for non-sterile registered medicines
- Webinar presentation: Regulation in times of a pandemic
- Webinar presentation: Overview of GMP regulatory activities
- Webinar presentation: Inspection reliance
- Webinar presentation: Remote GMP inspections: Current feedback and future considerations
- Webinar presentation: Clean room requirements for biologicals
- Webinar presentation: Code tables for GMP Clearances
- Webinar presentation: GMP overview and an update on PIC/S guide to GMP for medicinal products version 14
- Webinar presentation: How to improve your GMP compliance for listed medicines and GMP implementation of TGOs 92 and 101
- Webinar presentation: GMP licence applications
- Webinar presentation: GMP clearance - Common deficiencies
- Webinar presentation: Sterile medicines - lessons from StrugglePharm
- Webinar presentation: Manufacturing investigational medicinal products
- TGA presentations: Good Manufacturing Practice (GMP) Forum 2021, Online, 12-14 May 2021
- Presentation: Good manufacturing practice inspections during the pandemic - an Australian perspective
Topics
Latest articles
-
Consent relating to listed medicines that contain whole live microorganisms as an active ingredient
NoticesThis consent is given under sections 14 and 14A of the Therapeutic Goods Act 1989. -
Automatic extension of Mutual Recognition Agreement (MRA) Good Manufacturing Practice (GMP) clearances
NoticesMRA GMP clearances that are expiring on 31 December 2024 will be automatically extended. -
Nitrosamine impurities acceptable intakes update - October 2024
NewsThe TGA is updating information for nitrosamine impurities in medicines including acceptable intakes (AI).